Rise Nano Optics Gains FDA Class I Classification for SPECTRAGUARD Lens Filtering 100% UV, 90% Blue Light
Rise Nano Optics received FDA Class I classification for its SPECTRAGUARD nano-optic lens, confirming biocompatibility and 100% UV plus up to 90% blue-light filtration in the 400-600 nm range. U.S. FDA registration clears import and multi-channel launch targeting eye care professionals, optical labs and DTC sales in a $160 billion eyewear market.
1. FDA Class I Device Classification
Rise Nano Optics’ SPECTRAGUARD™ nano-optic lens technology has been registered and classified as a Class I medical device by the FDA following successful biocompatibility testing. The patented lens architecture selectively filters 100% of ultraviolet light and up to 90% of high-energy visible wavelengths between 400–600 nm while preserving natural color accuracy.
2. U.S. Commercial Launch Strategy
FDA registration authorizes U.S. import and enables a multi-channel rollout under the company’s new chief commercial officer. The commercialization plan targets eye care professionals, optical labs, lens manufacturers and direct-to-consumer platforms to drive early adoption and scale in North America.
3. Market Opportunity and Intellectual Property
The United States represents a core segment of the $160 billion global eyewear market, where more than 90% of adults use corrective or protective eyewear. Rise holds multiple patents covering its nano-particle formulations, lens architecture and scalable manufacturing processes, providing a robust IP foundation for its growth strategy.